Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951251 | 1.00 | HDAC2 (0.40) | HDAC2HDAC1ALDH1A1KDM4EHPGD | |
| SCHEMBL9951152 | 0.80 | CYP3A4 (0.33) | HDAC2HDAC1ALDH1A1KDM4EHPGD | |
| SCHEMBL9951148 | 0.72 | HDAC1 (0.32) | HDAC2HDAC1ALDH1A1KDM4EHPGD | |
| SCHEMBL10188806 | 0.72 | PTGS2 (0.35) | KDM4EGAAPTGS2 | |
| SCHEMBL9950483 | 0.71 | MAPT (0.38) | ALDH1A1KDM4EHPGDLMNAKMT2A | |
| SCHEMBL2118681 | 0.70 | HCRTR1 (0.38) | — | |
| SCHEMBL2118678 | 0.70 | HCRTR1 (0.38) | — | |
| SCHEMBL2118674 | 0.70 | HCRTR1 (0.38) | — | |
| SCHEMBL9951554 | 0.68 | HTR2A (0.35) | MAPTPTGS2 | |
| SCHEMBL9951558 | 0.68 | HTR2A (0.35) | MAPTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HDAC2 737/4885HDAC1 841/4885ALDH1A1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.